OMEROS CORP Increase (Decrease) in Other Deferred Liability
OMEROS CORP (OMER) reported Increase (Decrease) in Other Deferred Liability of -$435.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherDeferredLiability · last filed 2019-03-01
- OMEROS CORP increase (decrease) in other deferred liability for the quarter ending 2013-03-31 was $87.00K, a 97.16% decline year-over-year.
- OMEROS CORP increase (decrease) in other deferred liability for the quarter ending 2012-03-31 was $3.06M.
- OMEROS CORP increase (decrease) in other deferred liability for fiscal 2018 was -$435.00K.
- OMEROS CORP increase (decrease) in other deferred liability for fiscal 2017 was -$96.00K, a 359.46% decline from fiscal 2016.
- OMEROS CORP increase (decrease) in other deferred liability for fiscal 2016 was $37.00K, a 76.43% decline from fiscal 2015.
- OMEROS CORP increase (decrease) in other deferred liability for fiscal 2015 was $157.00K, a 82.59% decline from fiscal 2014.
| Period end | Increase (Decrease) in Other Deferred Liability 3 month | Increase (Decrease) in Other Deferred Liability 12 month | Increase (Decrease) in Other Deferred Liability 12 month as first filed |
|---|---|---|---|
| 2018-12-31 | -$435.00K 10-K · filed 2019-03-01 | ||
| 2017-12-31 | -$96.00K 10-K · filed 2019-03-01 | ||
| 2016-12-31 | $37.00K 10-K · filed 2019-03-01 | -$65.00K 10-K · filed 2017-03-16 | |
| 2015-12-31 | $157.00K 10-K · filed 2017-03-16 | ||
| 2014-12-31 | $902.00K 10-K · filed 2017-03-16 | ||
| 2013-12-31 | $3.50M 10-K · filed 2016-03-15 | ||
| 2013-03-31 | $87.00K 10-Q · filed 2013-05-09 | ||
| 2012-12-31 | $4.64M 10-K · filed 2015-03-16 | $3.69M 10-K · filed 2013-03-18 | |
| 2012-03-31 | $3.06M 10-Q · filed 2013-05-09 | ||
| 2011-12-31 | $0.00 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |